IPSEN (OTCMKTS:IPSEY) Short Interest Up ∞ in August

IPSEN (OTCMKTS:IPSEY) was the recipient of a significant growth in short interest in August. As of August 14th, there was short interest totaling 1,164 shares, a growth of ∞ from the July 30th total of 0 shares. Based on an average trading volume of 715 shares, the days-to-cover ratio is presently 1.6 days. Approximately 0.0% of the shares of the company are sold short.

IPSEN Stock Performance

OTCMKTS IPSEY opened at $49.15 on Tuesday. The firm has a 50-day moving average of $46.34 and a 200-day moving average of $46.57. IPSEN has a 52-week low of $32.02 and a 52-week high of $51.10.

Analyst Ratings Changes

A number of brokerages have recently commented on IPSEY. HC Wainwright reissued a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Jefferies Financial Group cut shares of IPSEN from a “hold” rating to a “moderate sell” rating in a report on Sunday, August 2nd. Zacks Research upgraded shares of IPSEN to a “hold” rating in a research note on Friday, May 29th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a report on Thursday, May 14th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, IPSEN has an average rating of “Hold”.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).